Shares of MannKind Co. (NASDAQ:MNKD) gapped up prior to trading on Thursday . The stock had previously closed at $2.06, but opened at $2.11. MannKind shares last traded at $2.24, with a volume of 5466583 shares changing hands.
MNKD has been the topic of several recent analyst reports. ValuEngine upgraded shares of MannKind from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. Svb Leerink initiated coverage on shares of MannKind in a report on Friday, February 22nd. They issued an “outperform” rating and a $3.00 price target on the stock. Leerink Swann initiated coverage on shares of MannKind in a report on Friday, February 22nd. They issued an “outperform” rating and a $3.00 price target on the stock. Finally, BidaskClub upgraded shares of MannKind from a “hold” rating to a “buy” rating in a report on Thursday. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $3.06.
The firm has a market cap of $419.65 million, a P/E ratio of -3.73 and a beta of 2.68.
MannKind (NASDAQ:MNKD) last announced its earnings results on Tuesday, February 26th. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing the Zacks’ consensus estimate of $0.22 by ($0.28). During the same quarter in the previous year, the company posted ($0.28) EPS. Analysts expect that MannKind Co. will post -0.32 earnings per share for the current year.
Hedge funds have recently made changes to their positions in the company. CAPROCK Group Inc. bought a new stake in shares of MannKind during the 4th quarter valued at $42,000. Virtu Financial LLC bought a new stake in shares of MannKind during the 4th quarter valued at $50,000. Cambridge Investment Research Advisors Inc. boosted its holdings in shares of MannKind by 196.1% during the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 55,407 shares of the biopharmaceutical company’s stock valued at $59,000 after buying an additional 36,694 shares in the last quarter. Bank of America Corp DE boosted its holdings in shares of MannKind by 82.3% during the 2nd quarter. Bank of America Corp DE now owns 123,414 shares of the biopharmaceutical company’s stock valued at $235,000 after buying an additional 55,721 shares in the last quarter. Finally, Alliancebernstein L.P. boosted its holdings in shares of MannKind by 300.5% during the 3rd quarter. Alliancebernstein L.P. now owns 154,600 shares of the biopharmaceutical company’s stock valued at $283,000 after buying an additional 116,000 shares in the last quarter. Hedge funds and other institutional investors own 33.37% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “MannKind (MNKD) Shares Gap Up to $2.11” was originally reported by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://www.baseballdailydigest.com/news/2019/03/16/mannkind-mnkd-shares-gap-up-to-2-11.html.
About MannKind (NASDAQ:MNKD)
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients. It offers Afrezza, a dry powder formulation of human insulin that controls high blood sugar in adults with type 1 and type 2 diabetes in the United States.
Featured Article: What is the Difference Between Common Shares and Convertible Shares?
Receive News & Ratings for MannKind Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for MannKind and related companies with MarketBeat.com’s FREE daily email newsletter.